Logo image of VOR

VOR BIOPHARMA INC (VOR) Stock Fundamental Analysis

NASDAQ:VOR - Nasdaq - US9290331084 - Common Stock - Currency: USD

0.214  +0.01 (+3.78%)

After market: 0.22 +0.01 (+2.8%)

Fundamental Rating

2

Taking everything into account, VOR scores 2 out of 10 in our fundamental rating. VOR was compared to 557 industry peers in the Biotechnology industry. The financial health of VOR is average, but there are quite some concerns on its profitability. VOR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VOR has reported negative net income.
In the past year VOR has reported a negative cash flow from operations.
In the past 5 years VOR always reported negative net income.
VOR had a negative operating cash flow in each of the past 5 years.
VOR Yearly Net Income VS EBIT VS OCF VS FCFVOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

VOR's Return On Assets of -108.49% is on the low side compared to the rest of the industry. VOR is outperformed by 78.82% of its industry peers.
VOR's Return On Equity of -179.50% is on the low side compared to the rest of the industry. VOR is outperformed by 65.53% of its industry peers.
Industry RankSector Rank
ROA -108.49%
ROE -179.5%
ROIC N/A
ROA(3y)-57.36%
ROA(5y)-53.18%
ROE(3y)-78.63%
ROE(5y)-74.06%
ROIC(3y)N/A
ROIC(5y)N/A
VOR Yearly ROA, ROE, ROICVOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VOR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VOR Yearly Profit, Operating, Gross MarginsVOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

VOR has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, VOR has more shares outstanding
There is no outstanding debt for VOR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VOR Yearly Shares OutstandingVOR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
VOR Yearly Total Debt VS Total AssetsVOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -9.06, we must say that VOR is in the distress zone and has some risk of bankruptcy.
VOR's Altman-Z score of -9.06 is on the low side compared to the rest of the industry. VOR is outperformed by 71.81% of its industry peers.
VOR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.06
ROIC/WACCN/A
WACCN/A
VOR Yearly LT Debt VS Equity VS FCFVOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 3.88 indicates that VOR has no problem at all paying its short term obligations.
VOR has a Current ratio (3.88) which is comparable to the rest of the industry.
A Quick Ratio of 3.88 indicates that VOR has no problem at all paying its short term obligations.
VOR has a Quick ratio (3.88) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.88
Quick Ratio 3.88
VOR Yearly Current Assets VS Current LiabilitesVOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

VOR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.17%, which is quite good.
EPS 1Y (TTM)15.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 17.66% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y61.68%
EPS Next 2Y26.92%
EPS Next 3Y13.68%
EPS Next 5Y17.67%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VOR Yearly Revenue VS EstimatesVOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M
VOR Yearly EPS VS EstimatesVOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VOR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VOR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VOR Price Earnings VS Forward Price EarningsVOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VOR Per share dataVOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

VOR's earnings are expected to grow with 13.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.92%
EPS Next 3Y13.68%

More info and screens

0

5. Dividend

5.1 Amount

VOR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VOR BIOPHARMA INC

NASDAQ:VOR (6/18/2025, 8:00:01 PM)

After market: 0.22 +0.01 (+2.8%)

0.214

+0.01 (+3.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners48.76%
Inst Owner Change-1.5%
Ins Owners0.57%
Ins Owner Change95.98%
Market Cap26.74M
Analysts50
Price Target0.32 (49.53%)
Short Float %4.93%
Short Ratio1.61
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-32.55%
Min EPS beat(2)-52.48%
Max EPS beat(2)-12.62%
EPS beat(4)2
Avg EPS beat(4)-15.2%
Min EPS beat(4)-52.48%
Max EPS beat(4)2.83%
EPS beat(8)3
Avg EPS beat(8)-7.73%
EPS beat(12)5
Avg EPS beat(12)-4.02%
EPS beat(16)8
Avg EPS beat(16)-1.76%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-96.42%
PT rev (3m)-97.31%
EPS NQ rev (1m)-9.69%
EPS NQ rev (3m)17.5%
EPS NY rev (1m)0%
EPS NY rev (3m)40.98%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.4
P/tB 0.4
EV/EBITDA N/A
EPS(TTM)-1.51
EYN/A
EPS(NY)-0.66
Fwd EYN/A
FCF(TTM)-0.81
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0
BVpS0.53
TBVpS0.53
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -108.49%
ROE -179.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-57.36%
ROA(5y)-53.18%
ROE(3y)-78.63%
ROE(5y)-74.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.15%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.88
Quick Ratio 3.88
Altman-Z -9.06
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)123.83%
Cap/Depr(5y)265.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.22%
EPS Next Y61.68%
EPS Next 2Y26.92%
EPS Next 3Y13.68%
EPS Next 5Y17.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.68%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-8.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.9%
OCF growth 3YN/A
OCF growth 5YN/A